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OBJECTIVE—Obesity is associated with increased activation of
the c-Jun NH2-terminal kinase (JNK) in several metabolic organs,
including adipose tissue, liver, and skeletal muscle. In this study,
we aimed to deﬁne the role of JNK activation in adipose tissue in
the development of obesity-related insulin resistance.
RESEARCH DESIGN AND METHODS—Transgenic mice with
adipose tissue–speciﬁc overexpression of dominant-negative JNK
(ap2-dn-JNK) under the transcriptional control of the aP2 gene
promoter were generated and subjected to metabolic character-
ization together with the wild-type littermates.
RESULTS—On a high-fat diet (HFD), the ap2-dn-JNK mice dis-
played a marked suppression of both JNK1 and JNK2 activation
in their adipose tissue, accompanied by a marked reduction in
weight gain, fat mass, and size of the adipocytes. The transgenic
mice were resistant to the deleterious impact of an HFD on sys-
temic insulin sensitivity, glucose tolerance, and hepatic steatosis.
Reduced hepatic gluconeogenesis was evident in in vivo and ex
vivo studies and showed greater insulin-induced glucose uptake
in skeletal muscles. These changes were accompanied by re-
duced macrophage inﬁltration in adipose tissue, decreased
production of proinﬂammatory adipokines, and increased expres-
sion of adiponectin. Indirect calorimetry analysis showed that the
transgenic mice had signiﬁcant increases in oxygen consumption
and reductions in respiration exchange rates compared with their
wild-type littermates.
CONCLUSIONS—Selective suppression of JNK activation in
adipose tissue alone is sufﬁcient to counteract HFD-induced
obesity and its associated metabolic dysregulations, in part
through an increase in energy expenditure and a decrease in
systemic inﬂammation. Diabetes 60:486–495, 2011
O
besity is a major risk factor of type 2 diabetes.
Although the detailed molecular events linking
obesity to type 2 diabetes are not well under-
stood, mounting evidence suggests that chronic
inﬂammation in the adipose tissue plays a major role (1,2).
Systemic inﬂammation, characterized by elevated circu-
lating concentrations of proinﬂammatory markers such as
C-reactive protein, is frequently observed in obesity and
predicts the development of type 2 diabetes (3). Adipose
tissue is now recognized as the predominant contributor
of systemic inﬂammation observed in obese states. Obesity
is associated with macrophage inﬁltration in adipose tis-
sue (4) and dysregulated production of adipokines (2,5),
with increased production of proinﬂammatory adipokines/
cytokines, which induce insulin resistance, such as tumor
necrosis factor (TNF)-a, interleukin (IL)-6, monocyte
chemotactic protein (MCP)-1, and adipocyte fatty acid–
binding protein (A-FABP), and decreased production of
adiponectin, an anti-inﬂammatory and insulin-sensitizing
adipokine.
Recent studies (2,6) in rodents suggest that c-Jun NH2-
terminal kinase (JNK) is a key player in adipose tissue
inﬂammation and provides a link between nutrient excess,
inﬂammation, and impaired insulin signaling. The JNK
group of serine/threonine kinases, JNK1, -2, and -3, belongs
to the mitogen-activated protein kinase family (7); JNK1
and JNK2 are widely distributed, whereas JNK3 is re-
stricted to the brain, heart, testis, and pancreatic islets.
Through the phosphorylation of various transcription fac-
tors, including c-Jun and JunB, JNKs are involved in the
regulation of development, immune response, cell sur-
vival, and apoptosis (7). Recently, it has been observed
that in ob/ob rodents JNK activity is increased in liver,
muscle, and, markedly, in adipose tissue (8). This is not
unexpected because various stimuli that activate JNK, in-
cluding fatty acids, cytokines (notably TNF-a), and endo-
plasmic stress (9), are increased in obesity. Activated JNK
induces serine phosphorylation of insulin receptor sub-
strate-1 at Ser307, which suppresses tyrosine phosphory-
lation, leading to impaired insulin action. Genetic deletion
of JNK1 is associated with reduced adiposity and pro-
tection against insulin resistance and type 2 diabetes
in both diet-induced and genetic obesity, as well as in-
creased adiponectin levels and reduced expression of
proinﬂammatory cytokines (8,10). Adenovirus-mediated
delivery of dominant-negative JNK (dn-JNK) or wild-type
JNK in ob/ob mice has conﬁrmed the role of JNK activation
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ORIGINAL ARTICLEin the liver in enhancing systemic insulin resistance through
increasing hepatic glucose output (11). More recently, tar-
geted deletion of JNK1 in the muscle (12) and reciprocal
adoptive transfer experiments (13) show that JNK1 in
muscles and macrophages also contribute to insulin re-
sistance, but not adiposity, in mice with high-fat diet
(HFD)-induced obesity. On the other hand, adipocyte-
speciﬁcd e l e t i o no fJNK1 improves insulin sensitivity in
the liver and adipose tissue but, again, has no impact on
adiposity (14).
The improvement in insulin resistance in ob/ob mice
after treatment with selective inhibitors of JNKs (6,15)
suggests that the suppression of JNK activation is an
attractive therapeutic approach in the management of
obesity-related type 2 diabetes. In this study, using an
alternative strategy of JNK inactivation, we have dem-
onstrated, for the ﬁrst time, that selective suppression of
both JNK1 and JNK2 activation in adipose tissue alone
can protect against both increased adiposity and insulin
resistance induced by an HFD.
RESEARCH DESIGN AND METHODS
Antibodies and chemicals. Rabbit polyclonal antibodies against total JNK1/2
and phospho-JNK1/2 and total Akt and phosphor-Akt (Thr308) were from Cell
Signaling Technology, and antibodies against hemagglutinin (HA) tag and
b-actin were from Sigma. Murine monoclonal antibody against F4/80 was from
Serotec. The JNK Activity Assay Kit was purchased from Abcam. Glucose,
insulin, and sodium pyruvate were from Sigma. [1-
14C]Oleic acid, [
14C]man-
nitol, and 2-deoxy-D-[
3H]glucose were purchased from Amersham.
Generation of transgenic mice. A 3.3-kb cDNA fragment encoding HA-tag-
ged JNKK2 (KM)-JNK1 fusion protein, in which lysine 149 in the ATP domain of
the JNKK2 moiety was replaced by methionine, was released from the
pSRa3HA-JNKK2 (K149M)-JNK1 construct (16) by digestion with Bgl Ia n d
Hind III and was then subcloned into a transgenic vector under the control of
the 5.4-kb aP2 promoter (17). The transgenic vector was digested by Pvu I, and
an 8.7-kb fragment carrying the aP2 promoter and the transgene was isolated
and microinjected into the pronucleus of fertilized eggs of C57BL/63CBA
mice, as described previously (17). Transgenic founders were identiﬁed by
PCR analysis using a pair of primers listed in Supplemental Table 1. Four
independent transgenic lines were established. The transgenic founders were
backcrossed with C57BL/6J for at least six generations. All experimental
procedures were approved by the committee on the use of live animals for
teaching and research of the University of Hong Kong and were carried out in
accordance with the guide for the care and use of laboratory animals.
Animal maintenance and metabolic studies. The transgenic mice and wild-
type littermates were maintained on 12-h light and dark cycles under controlled
environmental settings (23 6 1°C), with free access to water. All experiments
were conducted on littermate-controlled male mice with a uniform C57BL/6 J
background. In this study, all mice, starting at the age of 4 weeks, were
maintained on a standard chow (13% of calories from fat, D5053; LabDiet) or
an HFD (45% of calories from fat, D12451; Research Diets) for 20 weeks.
Glucose tolerance tests, insulin tolerance tests, and pyruvate tolerance tests
were conducted as previously described (18). Blood glucose levels were de-
termined in tail blood using the Ascensia Elite XL blood glucose meter (Bayer
Health Care). Fasting serum triglycerides and free fatty acid levels were an-
alyzed with Triglyceride Liquicolor (Stanbio Laboratory) and the Free Fatty
Acid Half Micro Test (Roche), respectively. Serum insulin, leptin, A-FABP, and
adiponectin levels were determined using enzyme-linked immunosorbent as-
say kits (Mercodia and Biovender).
Isolation and culture of murine peritoneal macrophages. Peritoneal
macrophages were prepared from ap2-dn-JNK mice and their wild-type lit-
termates that had previously been injected with 2 mL Brewer thioglycollate
broth medium (4 g/100 mL) (Difco Laboratories) for 2 days followed by lavage
of the peritoneal cavity with 5 mL of PBS. The peritoneal cells were washed
twice and seeded at densities of 6 3 10
5 cells/mL in RPMI-1640 medium
(Gibco) containing 10% (vol/vol) FCS. The macrophages were allowed to ad-
here for 3 6 4 h in a 5% CO2-humidiﬁed atmosphere prior to assay for the JNK
activity.
JNK activity assay. JNK activity in peritoneal macrophages and adipose
tissue was examined via immunoprecipitation of JNK kinase and incubation
with the substrate glutathione S-transferase (GST)-c-Jun immobilized on GST-
agarose beads, following the instructions of the JNK activity assay kit from
Abcam. After incubation with an antibody speciﬁc to JNK1 and JNK2 for
FIG. 1. Generation and characterization of aP2-dn-JNK transgenic (Tg) mice. A: Schematic representation of the aP2-dn-JNK transgenic con-
struct. The dn-JNK cDNA, in which lysine 149 in the ATP domain of the JNKK2 moiety was replaced by Met to create the HA-JNKK2(K149M)
JNK1, was subcloned downstream of the 5.4-kb aP2 promoter/enhancer and upstream of the hGH polyadenylation signals. B: Detection of the dn-
JNK transgene by PCR analysis in mice. Speciﬁc fragments of 653 bp spanning from the aP2 promoter to the JNKK2 gene was ampliﬁed.
2/2,
transgene negative;
2/+, transgene positive; L, 1-kb DNA ladder; PC, plasmid DNA positive control; WT, wild-type littermates. C: Expression of the
dn-JNK transgene by RT-PCR. The presence of the dn-JNK mRNA was analyzed in various tissues of aP2-dn-JNK transgenic mice (10 weeks old)
by RT-PCR using speciﬁc primers for the dn-JNK transgene (n = 5). EPI, epididymal adipose fat; PRF, perirenal fat; SU, subcutaneous adipose fat.
D: Conﬁrmation of the dn-JNK protein expression by immunoblotting (n = 4). Protein extracts from various tissues were subjected to Western
blotting with anti-HA antibody.
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were washed extensively in a lysis buffer, followed by a kinase assay buffer,
and the activity of the bound JNK was detected with the addition of c-Jun
protein/ATP for 4 h at 30°C. The reaction products were subjected to SDS-
PAGE separation, and the phosphorylated c-Jun protein was detected using
the rabbit anti–phospho–c-Jun (Ser73)-speciﬁc antibody.
Measurement of [
3H]2-deoxyglucose uptake in skeletal muscle and
primary adipocytes. Basal and insulin-stimulated glucose uptake was mea-
sured as described (19), with a few modiﬁcations. The soleus and the extensor
digitorum longus muscles were carefully excised from anesthetized mice and
incubated for 20 min at 30°C in 2 mL of pregassed (95% O2,5 %C O 2) Krebs-
Henseleit buffer (KHB) containing 0.1% BSA, 8 mmol/L glucose, and 32 mmol/L
mannitol. Muscles were then transferred to a glucose-free KHB buffer con-
taining 0.1% BSA, 4 mmol/L pyruvate, and 36 mmol/L mannitol and incubated in
the presence or absence of 60 mU/mL insulin for 20 min. Afterward, muscles
were incubated for 20 min in a similar KHB buffer containing 2-deoxy-D-
[
3H]glucose (2.25 mCi/mL) and [
14C]mannitol (0.3 mCi/mL) in the presence or
absence of insulin. After all incubations, muscle strips were removed, trimmed
of tendons, blotted to remove excess ﬂuid, and weighed. The muscle samples
were then digested in 1 mL of 1 mol NaOH for 10 min at 95°C. A total of 200 mL
of the digested muscle was then subjected to liquid scintillation counting to
calculate the intracellular accumulation of 2-deoxy-D-[
3H]glucose. Glucose
uptake in primary adipocytes isolated from epididylmal adipose tissue was
described elsewhere (17).
Indirect calorimetry. Mice were individually housed in metabolic chambers
maintained at 20–22°C in a 12-h light/12-h dark cycle. Six-week-old mice were
fed with an HFD and tap water ad libitum using a computer-controlled open-
circuit indirect calorimetry system (Oxymax; Columbus Instruments) with an
airﬂow of 0.6 L/min and sample ﬂow of 0.5 L/min. After the mice had adapted
to the environment of the metabolic chamber for 48 h, metabolic parameters
(whole-body oxygen consumption rates and respiration exchange rates) were
assessed as described (17).
Quantitative real-time PCR. Total RNA from various organs of mice was
isolated using the TRIzol reagent (Invitrogen) and treated with RNase-free
DNase (Promega, Madison, WI) at 37°C for 30 min to remove genomic DNA
and was then subjected to reverse transcription and real-time PCR analysis on
an ABI Prism 7000 instrument (Applied Biosystems), as described (17,20).
Primers used for real-time PCR are listed in Supplemental Table 1.
Immunohistochemistry and histological analysis. Adipose tissue was ﬁxed
in freshly prepared 4% paraformaldehyde in PBS overnight at 4°C and em-
bedded in parafﬁn for thin sectioning. Immunocytochemistry analysis for
macrophage markers and Oil red O staining analysis for lipid accumulation in
the liver sections were detailed elsewhere (17,21).
Statistical analysis. The data were expressed as means 6 SE. Statistically
signiﬁcant differences between two groups were assessed by one-way ANOVA
or the Student t test, as appropriate. A P value ,0.05 indicated a signiﬁcant
difference.
RESULTS
Transgenic mice with adipose tissue–speciﬁc overex-
pression of dn-JNK exhibit lipopolysaccharide (LPS)
reduced JNK activity in obese adipose tissue and
LPS-stimulated peritoneal macrophages. First, we
generated transgenic mice overexpressing HA-tagged dn-
JNK under the transcriptional control of the A-FABP gene
(aP2) promoter, which has been routinely used to drive
adipose tissue–speciﬁc expression of foreign genes in
transgenic mice (22). JNKK2 (KM), in which methionine
(Met) replaces (Lys) 149 in the ATP-binding domain of
c-Jun NH2-terminal kinase kinase2 (JNKK2) that stimulates
JNK activation, has been demonstrated to result in the
FIG. 2. The activity of both JNK1 and JNK2 was reduced in peritoneal macrophages and adipose tissue of aP-2dn-JNK transgenic (Tg) mice. A: Cell
lysates harvested from peritoneal macrophages stimulated with or without LPS (100 ng/mL, 10 min) were subjected to immunoprecipitation using an
antibody speciﬁc to JNK1 or JNK2, followed by JNK activity assay using GST–c-Jun as a substrate. B: Epididymal fat from aP2-dn-JNK or wild-type
(WT) littermates on the standard chow (SC) or the HFD for 8 weeks were homogenized and assayed for the activity of JNK1 and JNK2 as in A.T h eb a r
charts below the blots were the quantitative analysis of JNK1 and JNK2 activity. IB, immunoblots. **P < 0.01 vs. wild-type littermates (n =5 ) .
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sion protein, dn-JNK, functions as a dominant-negative Jun
kinase by competing with endogenous JNK1/2. Our trans-
genic construct consisted of 5.4 kb of the 59 ﬂanking fat-
speciﬁc regulatory region of the aP2 gene and 21 bp of its
ﬁrst exon and the cDNA of dn-JNK (Fig. 1A). The trans-
genic construct was introduced into pronuclei, and four
transgenic founders were identiﬁed by genotyping (Fig.
1B). Both mRNA and protein expression of dn-JNK were
restricted mainly in white adipose tissue (WAT) and brown
adipose tissue (BAT) (Fig. 1C and D, left panel)a n di n
isolated peritoneal macrophages of the transgenic mice
(Fig. 1D, right panel). On the contrary, neither the mRNA
nor protein of the transgene was detectable in a panel of
other major insulin-responsive tissues, except for a trace
amount of dn-JNK expression in the spleen.
The transgenic expression of dn-JNK had no obvious
effect on the activity of either JNK1 or JNK2 in unstimulated
peritoneal macrophages (Fig. 2A) or on WAT in mice fed
a standard chow (Fig. 2B). On the other hand, LPS-induced
activation of both JNK1 and JNK2 in peritoneal macro-
phages of the transgenic mice was markedly attenuated.
FIG. 3. The aP2-dn-JNK mice were less obese than control mice under the HFD, displaying decreased fat mass and triglyceride contents in adipose
tissue. A: Body weight changes on standard chow (SC) or HFD (HF) over 24 weeks in aP2-dn-JNK transgenic (Tg) mice and their wild-type (WT)
littermates. B: Caloric intake, as calculated by food intake per mouse per week (g/mouse/week) 3 3.07 kcal/g on the standard chow and 3 4.73 kcal/g
on the HFD. C: Fat-pad weights in aP2-dn-JNK and wild-type littermates, as measured after dissection at the age of 24 weeks and presented as
percentage of total body weight. Insert: Adiposity index, calculated as the total weight of fat pads divided by total body weight. Fat pads: BAT,
subcutaneous (SU), epididymal (EPI), perirenal (PRF), interscapular (Int), WAT, and gluteal fat (Glu). D: Representative images of hematoxylin
and eosin–stained sections of epididymal WAT and interscapular BAT on the HFD at the age of 24 weeks. Scale bar: 50 mm. E: The size of adi-
pocytes quantiﬁed using NIH ImageJ software. F: Triglyceride contents in epididymal fat pads and brown fat pads. *P < 0.05; **P < 0.01 vs. wild-
type littermates (n =6 –8). A and B were analyzed by ANOVA; C, E,a n dF were analyzed by the Student t test. (A high-quality color representation
of this ﬁgure is available in the online issue.)
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adipose tissue of the transgenic mice was also reduced to
a level similar to that in lean mice, suggesting that trans-
genic expression of dn-JNK driven by the aP2 promoter is
sufﬁcient to inhibit the activation of both endogenous
JNK1 and JNK2 in adipocytes and macrophages.
Adipose tissue–selective inactivation of JNK protects
against HFD-induced obesity and its related metabolic
disorders. On the standard chow, there was no obvious
difference in body weight gain between the ap2-dn-JNK
mice and their wild-type littermates (Fig. 3A). The ap2-dn-
JNK mice had much less HFD-induced weight gain com-
pared with age-matched littermates, with the difference in
body weight being signiﬁcant from the age of 10 weeks,
despite similar caloric intake (Fig. 3B). The various fat
depots weighed less in the ap2-dn-JNK mice, being sig-
niﬁcantly different from those of wild-type littermates in
both WAT (subcutaneous and perirenal depots) and inter-
scapular BAT (Fig. 3C). The adiposity index of ap2-dn-JNK
mice was signiﬁcantly reduced, compared with their wild-
type littermates (P , 0.05) (Fig. 3C, insert), suggesting that
ap2-dn-JNK mice were resistant to HFD-induced obesity.
Real-time PCR analysis demonstrated that the expres-
sion of several genes involved in adipogenesis, including
necdin, preadipocyte factor, peroxisome proliferator–
activated receptor-g, CCAAT/enhancer-binding protein-a,
and A-FABP, was not signiﬁcantly different between
ap2-dn-JNK mice and their wild-type littermates on an HFD
in several types of adipose tissue (Supplementary Fig. 1),
suggesting that JNK inactivation in adipose tissue did not
impair adipocyte differentiation. On the other hand, his-
tological analysis revealed that the ap2-dn-JNK mice had
smaller adipocytes in the epididymal fat pads, as well as
in BAT (Fig. 3D and E). Furthermore, the triglyceride
contents of WAT and BAT were signiﬁcantly reduced in
ap2-dn-JNK mice, relative to their wild-type littermates
(Fig. 3F).
The ap2-dn-JNK mice are protected from HFD-
induced insulin resistance and glucose intolerance.
An intraperitoneal glucose test was performed to com-
pare the glucose tolerance of ap2-dn-JNK and wild-type
mice. When fed with a standard chow, there was no ob-
vious difference between the two groups of mice (Fig. 4A).
In contrast, the ap2-dn-JNK transgenic mice were pro-
tected from HFD-induced glucose intolerance (Fig. 4B and
C). The intraperitoneal insulin tolerance test also showed
no signiﬁcant difference in insulin sensitivity in the two
groups of mice on the standard chow (Fig. 4D) but sig-
niﬁcantly better insulin sensitivity in the ap2-dn-JNK mice
on HFD (Fig. 4E and F). The beneﬁcial metabolic effects
observed in the ap2-dn-JNK transgenic mice also included
lower fasting glucose and insulin levels and homeostasis
FIG. 4. Adipose tissue–selective inactivation of JNK improves in vivo glucose homeostasis and insulin sensitivity. The in vivo glucose homeostasis
and insulin sensitivity were examined in aP2-dn-JNK transgenic (Tg) mice and their wild-type (WT) littermates at the age of 24 weeks while on
standard chow (SC) or the HFD (HF) diet for 20 weeks. A–C: Glucose tolerance test (GTT). Mice fasted overnight were injected intraperitoneally
with glucose (1 mg/g). Blood glucose concentration was measured at the indicated times in standard chow group (A), HFD-fed group (B), and
represented as the area under the curve (C). D–F: Insulin tolerance test (ITT). Mice fasted overnight were injected intraperitoneally with insulin
(0.75 mU/g). Blood glucose concentration was measured at the indicated times in standard chow (D) and HFD-fed (E) mice and represented as the
area under the curve (F).
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(Supplementary Table 2).
Inactivation of JNK increases insulin-stimulated
glucose uptake in skeletal muscles. We next investi-
gated whether the improvement in insulin-mediated glucose
uptake in skeletal muscle contributed to the phenotypic
changes in the transgenic mice. This analysis showed that
there were no signiﬁcant differences in the basal rates
of Akt phosphorylation (Thr308) and glucose uptake be-
tween the aP2-dn-JNK and wild-type mice in either soleus
(Fig. 5A and B) or extensor digitorum longus muscles (data
not shown) when fed either a standard chow or HFD.
In wild-type ob/ob mice on an HFD, insulin-evoked Akt
phosphorylation and glucose uptake were decreased by
approximately 55 and 61%, respectively, compared with
lean controls (Fig. 5A and B). In contrast, the levels of in-
sulin-stimulated Akt phosphorylation and glucose uptake in
the transgenic mice on the HFD were comparable to those
in lean mice fed a standard chow, suggesting that the
protection against HFD-induced glucose tolerance in the
transgenic mice was attributed, at least in part, to an in-
crease in insulin-evoked glucose uptake in skeletal muscle.
Likewise, HFD-induced phosphorylation of JNK1/2 in skel-
etal muscle of the transgenic mice was signiﬁcantly at-
tenuated compared with wild-type littermates (Fig. 5C).
HFD-induced impairment in insulin-stimulated glucose
uptake in epididylmal WAT was also reversed in the
transgenic mice (Supplementary Fig. 2).
Inactivation of JNK attenuates HFD-induced hepatic
steatosis and glucose production. In the aP2-dn-JNK
transgenic mice on HFD, the livers were smaller and red-
dish in color, in contrast to the livers from their wild-type
littermates, which were bigger and had a yellowish-white
color. The ratio of the liver to body weight was signiﬁcant
lower in the transgenic mice (Fig. 6A). To further in-
vestigate the effects of overexpression of dn-JNK on HFD-
induced hepatic steatosis, we performed a hematoxylin
a n de o s i na n do i lr e dos t a i n i n ga n a l y s i s .A ss h o w ni nF i g .
6B, HFD induced a marked accumulation of lipid drop-
lets in hepatic cells accompanied by a loss of normal cell
morphology. Liver sections from aP2-dn-JNK transgenic
mice, in contrast, displayed a normal morphology and
an obvious reduction in the number of lipid-engorged he-
patic cells, similar to those in lean controls (Fig. 6B).
Compared with the wild-type mice, the ap2-dn-JNK
transgenic mice on the HFD had a signiﬁcantly lower glu-
cose production in response to pyruvate challenge (Fig. 6C).
The mRNA levels of the two key hepatic gluconeogenic
genes, including PEPCK and G6Pase,w e r es i g n i ﬁcantly
decreased in aP2-dn-JNK mice (Fig. 6D). Furthermore,
transgenic expression of dn-JNK in adipose tissue also re-
versed HFD-induced impairment in phosphorylation of Akt
(Thr308) and elevation in phosphorylation of JNK1/2
(Supplementary Fig. 3A and B).
Suppression of JNK reduces systemic and adipose
tissue–speciﬁci n ﬂammation. To investigate the role of
JNK in HFD-induced macrophage inﬁltration and aberrant
production of adipokines in the adipose tissue, we exam-
ined the expression of inﬂammatory markers in adipose
tissue and adipokines in blood from HFD-fed aP2-dn-JNK
and wild-type mice. The mRNA expression of F4/80,
a macrophage marker, and several proinﬂammatory cyto-
kines including IL-6, TNF-a, and MCP-1, were decreased in
the transgenic mice, compared with the wild-type mice
(Fig. 7A). This was further conﬁrmed by immunohis-
tochemisty using an anti-F4/80 antibody, showing that
aP2-dn-JNK mice had a markedly decreased macrophage
inﬁltration in adipose tissue (Fig. 7B). Furthermore, the
transgenic mice with dn-JNK expression in adipose tissue
on HFD feeding had signiﬁcantly lower serum levels of
leptin and A-FABP but higher levels of adiponectin, com-
pared with their wild-type littermates (Fig. 7C).
Adipose tissue inactivation of JNK increases energy
expenditure and lipid oxidation. To explore whether
increased energy expenditure contributed to the reduced
adiposity in aP2-dn-JNK mice, indirect calorimetry mea-
surements were performed in mice that had been on the
HFD for 2 weeks before the onset of obesity. The rate of
oxygen consumption (VO2) was higher in aP2-dn-JNK
mice over a 24-h period throughout the entire light/dark
FIG. 5. Effect of adipose tissue–selective JNK activation on HFD-induced impairment in insulin signaling in skeletal muscle. A: The soleus muscle
isolated from aP2-dn-JNK transgenic (Tg) mice and wild-type (WT) littermates at 16 weeks after the HFD (HF) or standard chow (SC) were
treated with insulin (60 mU/mL) for 10 min, followed by Western blot analysis for phosphorylated Akt (Thr308) and total Akt. B: Glucose uptake in
soleus muscle expressed as nmol/g wet weight/min. C: Western blot analysis for total and phosphorylated JNK1/2 in soleus muscle. The bar chart
below represents the quantitative analysis for fold changes in JNK1/2 phopshorylation relative to lean controls. *P < 0.05; **P < 0.01; ***P < 0.001
(n =5 –6).
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the whole day (Fig. 8A). The respiration exchange rate
(VCO2/VO2) was signiﬁcantly reduced in aP2-dn-JNK mice,
indicating an increase in lipid utilization (Fig. 8B). These
data revealed a signiﬁcant change at the level of energy
expenditure, together with an overall higher rate of lipid
oxidation and the preferential use of fat as a fuel source,
both of which might contribute to the reduced adiposity in
the transgenic mice.
DISCUSSION
The central role of JNK in the pathogenesis of obesity,
insulin resistance, and type 2 diabetes was ﬁrst suggested
by the demonstration that deletion of the JNK1 gene
(JNK1
2/2) leads to decreased adiposity and signiﬁcant
improvements in insulin sensitivity in both dietary and
genetic (ob/ob) mouse models of obesity (8). Subsequent
studies using targeted gene deletion (12,14) or reciprocal
adoptive transfer (13) approaches had provided evidence
for the contribution of JNK1 inactivation in the adipocytes
(14), skeletal muscles (12), and myeloid cells, such as
macrophages (14), to the protection against HFD-induced
insulin resistance seen in the JNK1
2/2 mice. However, none
of these subsequent studies with these approaches for se-
lective JNK1 deletion could reproduce the protection from
obesity evident in the conventional JNK1
2/2 mice. Simi-
larly, the adenovirus-mediated hepatic overexpression of
a dominant-negative (dn) form of JNK (11) also led to the
improvement in whole-body insulin resistance, largely sec-
ondary to a reduction in hepatic glucose production. Again,
this model of JNK inactivation in the liver, albeit only for 2
weeks, had no effect on weight gain in the treated animals.
The identity of the cell type responsible for the resistance to
obesity in the JNK
2/2 mice remains unknown. In this study,
we have demonstrated that in the ap2-dn-JNK transgenic
mice, selective inactivation of both JNK1 and JNK2 in the
adipose tissue and macrophages can reproduce all the
beneﬁcial metabolic effects observed in the JNK1
2/2 mice,
including protection from HFD-induced adiposity.
It should be noted that the resistance to obesity, to-
gether with enhanced insulin signaling, was also demon-
strated in the mice with heterozygous JNK1 deletion
together with complete JNK2 deletion (JNK
+/2 JNK2
2/2)
(10). The authors concluded that the most critical de-
terminant of insulin sensitivity, inﬂammation, and overall
weight gain in the mice on HFD is likely to be total JNK
kinase activity. The ﬁndings of our study suggest that the
selective suppression of total JNK kinase activity, in-
cluding inactivation of both JNK1 and JNK2, in adipose
tissue, resulting from the combined downregulation of
JNK in adipocytes and macrophages, is sufﬁcient to
FIG. 6. Effect of adipose tissue–speciﬁc JNK inactivation on HFD-induced changes in the liver. aP2-dn-JNK transgenic (Tg) mice and their wild-
type (WT) littermates were studied at the age of 24 weeks after 20 weeks of being fed with an HFD (HF) or standard chow (SC). A: The ratio of the
liver to total body weight (n =9 –13). B: Representative histological sections of liver stained with hematoxylin and eosin and Oil Red O. Scale bar:
50 mm. C: aP2-dn-JNK transgenic mice and wild-type littermates fasted overnight were injected intraperitoneally with pyruvate (1 mg/g). Blood
glucose concentration was measured at the indicated times (n =6 ) .D: Total RNA was isolated from the liver and the mRNA expression levels
of PEPCK and G6Pase genes were examined by quantitative RT PCR. The data were normalized against the amount of 18S rRNA in each sample.
*P < 0.05; **P < 0.01 (n =9 –13). (A high-quality digital representation of this ﬁgure is available in the online issue.)
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2/2
or JNK
+/2 JNK2
2/2 mice. Previous studies have demon-
strated considerable overlap in the biology and functions
of the macrophages and adipocytes in obesity, which ap-
pear to be important for the high level of coordination
between the inﬂammatory and metabolic pathways (2).
Our study would support the importance of a cross-talk
between the macrophages and adipocytes in mediating the
effect of the JNK activation in diet-induced obesity. This
information is of potential importance in drug development
programs using JNK as a therapeutic target for obesity and
type 2 diabetes.
In this study, the ap2-dn-JNK transgenic mice had de-
creased adipocyte size, which was also seen in the JNK1
2/2
mice (8). These transgenic mice had similar caloric intake
as their wild-type littermates but had an increased rate of
oxygen consumption and energy expenditure, ﬁndings that
were also proposed to explain for the resistance to obesity
in the JNK1
2/2 mice (13). A reduction in the respiration
exchange rate in the ap2-dn-JNK transgenic mice, sug-
gesting a preferential use of fat as a fuel source, provided
another possible mechanism for their reduction in adiposity
and triglyceride content in adipocytes. On the other hand,
an impairment in adipocyte differentiation did not appear
to play a signiﬁcant role in the reduced fat mass in these
transgenic animals.
The mechanism whereby inactivation of JNK in adipose
tissue leads to increased energy expenditure remains un-
known at this stage. In rodents, BAT is the primary site for
energy dissipation (23). In diet-induced obesity, inﬂam-
mation also occurs in BAT (24), which might impair its
thermogenic functions by inducing mitochondria dysfunc-
tion. In our transgenic mice, the dn JNK is also expressed
in high abundance in BAT. Therefore, it is possible that
inactivation of JNK in BAT can restore the thermogenic
activities impaired by the HFD. This hypothesis is cur-
rently under investigation in our laboratory.
On the HFD, the ap2-dn-JNK transgenic mice in this
study had improved glucose tolerance and insulin sen-
sitivity compared with their wild-type littermates. Their
improvement in insulin sensitivity was accompanied by
enhanced insulin-stimulated glucose uptake in the skele-
tal muscles, as well as reduced glucose production in
response by the liver to pyruvate challenge. They were
also protected against HFD-induced hepatosteatosis and
had reduced expression of the genes involved in gluco-
neogenesis, compared with HFD-fed wild-type littermates.
In a previous study, mice with selective adipocyte deletion
of the JNK1 gene also exhibited a protection against
hepatosteatosis and hepatic insulin resistance but had no
improvement in skeletal muscle insulin action. Further-
more, in the adipocyte-speciﬁc JNK1
2/2 mice, the degree
FIG. 7. Adipose tissue–speciﬁc inactivation of JNK alleviated the HFD-induced inﬂammatory changes. A: Quantitative RT PCR analysis for the gene
expression of F4/80 and the inﬂammatory cytokines MCP-1, TNF-a, and IL-6 in epididymal fat. Expression levels of all genes were normalized
against 18S rRNA. B: Immunohistochemical staining for F4/80 in epididymal fat tissue sections from aP2-dn-JNK transgenic (Tg) mice and wild-
type (WT) littermates. Scale bar: 50 mm. C: Serum leptin, adiponectin, and A-FABP levels in overnight-fasted aP2-dn-JNK transgenic mice and
wild-type littermates were measured by an enzyme-linked immunosorbent assay after being fed an HFD for 16 and 20 weeks, respectively. □, wild-
type littermates; ■, aP2-dn-JNK transgenic mice. *P < 0.05; **P < 0.01 vs. wild-type littermates (n =6 –8). (A high-quality color representation of
this ﬁgure is available in the online issue.)
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ilar to wild-type mice and only the production of IL-6, but
not TNF-a, was reduced relative to the wild-type mice. It
is obvious that the ap2-dn-JNK transgenic mice in our
study exhibited a much more marked protection against
the inﬂammatory changes induced by the HFD. Not only
was there a marked reduction in macrophage inﬁltration
in the adipose tissue, there was also evidence of reduced
expression of various proinﬂammatory cytokines and hor-
mones, including TNF-a, MCP-1, A-FABP, and leptin in ad-
dition to IL-6. On the other hand, the circulating level of the
anti-inﬂammatory adipokine, adiponectin, was increased.
JNK activation on the HFD was also reduced in the liver
and skeletal muscle, probably secondary to the reduced
circulating levels of JNK-activating adipokines, such as
TNF-a (9) and A-FABP (20), or to the decreased lipid con-
tents in these tissues. These data suggest that the sup-
pression of JNK activation in both the adipocytes and
macrophages is required for the protection against HFD-
induced insulin resistance in the skeletal muscles, prob-
ably consequent to the amelioration of adipose tissue
inﬂammation and adipokine dysregulation.
In conclusion, this study has provided the ﬁrst evidence
that selective suppression of both JNK1 and JNK2 activa-
tion in adipose tissue and macrophages can protect against
diet-induced obesity, through an increase in energy ex-
penditure and fat utilization. Our data also support the
importance of the cross-talk between the inﬂammatory
and metabolic pathways mediated by macrophages and
adipocytes in the development of obesity, insulin re-
sistance, and type 2 diabetes.
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